Monitor for an actual IND filing or formal FDA clearance announcement, which would be the next concrete catalyst. Without clinical data or a disclosed timeline, this update provides no new trading catalyst.
Price Chart
Executive Summary
Ernexa Therapeutics released a Virtual Investor segment discussing its pre-IND interaction with the FDA for lead candidate ERNA-101 in ovarian cancer. The filing is a non-data, narrative update on regulatory alignment and preclinical progress toward first-in-human studies, with no financial results, clinical data, or catalyst dates disclosed.
Key Facts
- Ernexa completed a pre-IND interaction with the FDA for ERNA-101 in ovarian cancer
- ERNA-101 is an allogeneic, off-the-shelf iMSC-based cell therapy engineered to express IL-7 and IL-15
- No clinical data, financial results, or specific timeline for IND filing or first-in-human study were disclosed
- The filing is a narrative update via a Virtual Investor segment, not a regulatory filing with hard milestones
Financial Impact
No financial figures disclosed; pre-revenue clinical-stage biotech with no reported revenue, earnings, or cash runway data
Risk Factors
- Preclinical stage with no clinical data; high risk of failure in first-in-human studies
- No disclosed cash runway or financing plan; potential dilution risk for a pre-revenue biotech
- Forward-looking statements carry typical biotech development and regulatory risks
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3386392 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | Press Release | $2.08 | awaiting T+5 | — | $1.94 (−6.51%) |
Oct 15, 2026 11d ago | 8-K | $2.09 $2.07 | ▼ −1.20% | ▼ −0.77% | $1.94 (−7.18%) |
Oct 1, 2026 25d ago | Press Release | $2.96 $2.49 | ▼ −15.88% | ▼ −17.18% | $1.94 (−34.46%) |
Sep 30, 2026 26d ago | Press Release | $3.20 $2.39 | ▼ −25.31% | ▼ −27.23% | $1.94 (−39.37%) |
Sep 16, 2026 5w ago | 8-K | $3.76 $3.62 | ▼ −3.72% | ▼ −4.32% | $1.94 (−48.40%) |
Sep 16, 2026 5w ago | 8-K | $3.76 $3.62 | ▼ −3.72% | ▼ −4.32% | $1.94 (−48.40%) |
Jul 14, 2026 14w ago | Press Release | $6.06 $5.43 | ▼ −10.40% | ▼ −9.10% | $1.94 (−67.99%) |
Jun 26, 2026 17w ago | 8-K | $7.03 $6.44 | ▼ −8.39% | ▼ −9.78% | $1.94 (−72.40%) |
Jun 17, 2026 18w ago | Press Release | $5.89 $6.30 | ▲ +6.96% | ▲ +8.00% | $1.94 (−67.06%) |
May 27, 2026 21w ago | Press Release | $11.14 $8.00 | ▼ −28.19% | ▼ −29.39% | $1.94 (−82.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers